Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis [NEXICART-3]

NCT07709715 is registered in ClinicalTrials.gov with Nexcella Inc. as lead sponsor.

NCT NCT07709715
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07709715 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis [NEXICART-3]
Lead sponsor
Nexcella Inc.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
January 31, 2027
Completion date
December 31, 2032
Enrollment
260 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

light chain (al) amyloidosis